Skip to content
OpenCapital
Get started

Veracyte VCYT Business Segments — R&D

Similar metrics at other companies

Indivior Pharmaceuticals, Inc. logo
INDVReportable Segment — R&D
$16M-27.3%
Pegasystems logo
PEGAReportable Segment — R&D
$82.05M+10.4%
Silicon Laboratories logo
SLABReportable Segment — R&D
$88.59M+0.4%
Travere Therapeutics, Inc. logo
TVTXReportable Segment — R&D
$57.09M+21.8%
Dolby Laboratories, Inc. logo
DLBReportable Segment — R&D
$53.84M+2.2%
Vaxcyte, Inc. logo
PCVXReportable Segment — R&D
$256.43M+147%

Other financials

Income statement

See full
Revenue$139.1M+21.5%
Gross profit$101.2M+27.2%
Operating income$22.6M+680%
Net income$28.7M+307%
EPS (diluted)$0.35+289%

Balance sheet

See full
Cash & equivalents$264.8M+41.0%
Total debt$39.3M-22.1%
Total equity$1.3B+12.5%
Total assets$1.4B+9.2%

Cash flow

See full
Operating cash flow$35.2M+557%
CapEx$3.0M+62.8%
Free cash flow$32.3M+810%

Valuation

See full
Market cap$4.29B+10.7%

Profitability

See full
Gross margin70.9%+2.9pp
Operating margin14.3%+9.2pp
Net margin16.2%+9.1pp
FCF margin28.7%+11.7pp

Returns & leverage

See full
Return on equity6.9%+4.1pp
Debt / equity0×0.0×
Current ratio9.3×+4.2×

Where this comes from

Reported directly by Veracyte in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: Veracyte’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Veracyte's business segments — r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Veracyte's business segments — R&D?
Veracyte (VCYT) reported business segments — R&D of $27.1M in Q1 2026.
How has Veracyte's business segments — R&D changed year-over-year?
Veracyte's business segments — R&D increased by 52.9% year-over-year, from $17.72M to $27.1M.
What is the long-term trend for Veracyte's business segments — R&D?
Over 3 years (2022 to 2025), Veracyte's business segments — R&D has grown at a 20.4% compound annual growth rate (CAGR), from $40.6M to $70.81M.
What does business segments — R&D mean?
The total investment made by the reportable segment into innovation, product development, and clinical or technical advancement. This metric is critical for evaluating the segment's long-term growth potential and competitive pipeline.